BRL Medicine Inc.

World's First! BRL Medicin's BCMA UCAR-T
Successfully Treats Neuromyelitis Optica Spectrum Disorder

MORE

The First Patient Treated with BRL Medicine’s
BRL-201 Therapy Achieves Over 5 Years of Cancer-Free Survival

MORE

World's first β0/β0 severe thalassemia patient cured for 5 years by BRL-101

MORE

BRL Medicine Awarded "First Prize of 2024 Shanghai Science and Technology Progress Award"

MORE

World's First! BRL Medicine's UCAR-T Successfully Treat Relapsed/Refractory Systemic Lupus Erythematosus

MORE

About BRL Medicine

At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, with many pipeline projects have entered into IND application stage.

Learn More